Erratum: (Arteriosclerosis, Thrombosis, and Vascular Biology (2012) 32 (236-246) DOI: 10.1161/ATVBAHA.111.241356);Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 236-246

  Moon, Byoung C ^a   Hernandez Ono, Antonio ^a   Stiles, Bangyan ^b   Wu, Hong ^c   Ginsberg, Henry N ^a,d  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Department of Molecular and Medical Pharmacology ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apolipoprotein B; insulin resistance; lipoproteins; steatosis; triglycerides

Indexed keywords

APOLIPOPROTEIN B; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; INSULIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FATTY LIVER; LIPOGENESIS; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION;

EID: 84862777481     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATV.0b013e31824d8afa     Document Type: Erratum

References (63)

1. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta. 1994;1215:9-32.
2. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176.
3. Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res. 2009;50(suppl): S162-S166.
4. Sparks CE, Sparks JD, Bolognino M, Salhanick A, Strumph PS, Amatruda JM. Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes. Metabolism. 1986; 35:1128-1135.
5. Patsch W, Franz S, Schonfeld G. Role of insulin in lipoprotein secretion by cultured rat hepatocytes. J Clin Invest. 1983;71:1161-1174.
6. Dashti N, Williams DL, Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res. 1989;30:1365-1373.
7. Roberts CK, Liang K, Barnard RJ, Kim CH, Vaziri ND. HMG-CoA reductase, cholesterol 7 α-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney Int. 2004;66:1503-1511.
8. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem. 1990;265: 8854-8862.
9. Pullinger CR, North JD, Teng B-B, Rifici VA, Ronhild de Brito AE, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res. 1989;30:1065-1076.
10. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem. 1997;272(49):30693-30702.
11. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem. 1996;313:567-574.
12. Brown AM, Gibbons GF. Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol. 2001;21:1656-1661.
13. Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab. 2000; 279:E1003-E1011.
14. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 1998;47(5):779-87.
15. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993;42:833-842.
16. Bartlett SM, Gibbons GF. Short-and longer-term regulation of very-lowdensity lipoprotein secretion by insulin, dexamethasone and lipogenic substrates in cultured hepatocytes: a biphasic effect of insulin. Biochem J. 1988;249:37-43.
17. Bjornsson OG, Duerden JM, Bartlett SM, Sparks JD, Sparks CE, Gibbons GF. The role of pancreatic hormones in the regulation of lipid storage, oxidation and secretion in primary cultures of rat hepatocytes: short-and long-term effects. Biochem J. 1992;281:381-386.
18. Siri P, Candela N, Ko C, Zhang Y, Eusufzai S, Ginsberg HN, Huang LS. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B-lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity and insulin resistance. J Biol Chem. 2001;276:46064-46072.
19. Bartels ED, Lauritsen M, Nielsen LB. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes. 2002;51: 1233-1239.
20. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Jarvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40:454-462.
21. Ginsberg HN, Le N-A, Gibson JC. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects: effect of weight loss. J Clin Invest. 1985;75:614-623.
22. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982;31:217-225.
23. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765.
24. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver diseases (NAFLD). Ann Med. 2009;41:265-278.
25. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288: E462-E468.
26. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoprotein in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115: 1343-1151.
27. Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36: 232-240.
28. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009;19: 291-302.
29. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 2002;277:17377-17380.
30. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7:125-134.
31. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H. Cre/loxP-mediated inactivation of the murine pten tumor suppressor gene. Genesis. 2002;32:149.
32. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim Y-J, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc Natl Acad Sci USA. 2004;101:2082-2087.
33. Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN. Aberrant hepatic expression of PPARβ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem. 2006; 281:37603-37015.
34. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008;118:316-332.
35. Bourgeois CS, Wiggins D, Hems R, Gibbons GF. VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. Am J Physiol. 1995;269:E208-E215.
36. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011;22:353-363.
37. Cohen JC, Horton JD, Hobbs HH. Human fatty liver: old questions and new insights. Science. 2011;332:1523.
38. Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res. 1993;34:167-179.
39. Craig WY, Nutik R, Cooper AD. Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2: the effect of exogenous lipoprotein. J Biol Chem. 1988;263:13880-13890.
40. Wu X, Sakata N, Dixon JL, Ginsberg HN. Exogenous VLDL stimulates apolipoprotein B from HepG2 cells by both pre-and post-translational mechanisms. J Lipid Res. 1994;35:1200-1210.
41. Salam WH, Wilcox HG, Heimberg M. Stimulation by oleic acid incorporation of L-[4,5-3H] leucine into very low density lipoprotein apoprotein by the isolated perfused rat liver. Biochem Biophys Res Commun. 1985;132:28-34.
42. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J. 1990;268:1-13.
43. Zhang Y-L, Hernandez-Ono A, Ko C, Yasunaga K, Huang L-S, Ginsberg HN. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids 1: differential effects of delivering fatty acids via albumin or remnant-like emulsion particles. J Biol Chem. 2004;279:19362-19374.
44. Melish J, Le N-A, Ginsberg H, Steinberg D, Brown WV. Dissociation of triglyceride and apoprotein-B production in very low density lipoproteins. Am J Physiol. 1980;239:E354-E362.
45. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002;277:34182-34190.
46. Horton JD, Shimano H, Hamilton RL, Brown MS, Goldstein JL. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest. 1999;103:1067-1076.
47. Basciano H, Miller A, Baker C, Naples M, Adell K. LXRα activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins. Am J Physiol Gastrointest Liver Physiol. 2009;297:G323-G332.
48. Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem. 2005;280: 21506-21514.
49. Millar JS, Stone SJ, Tietge UJ, Tow B, Billheimer JT, Wong JS, Hamilton RL, Farese RV Jr, Rader DJ. Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J Lipid Res. 2006;47:2297-2305.
50. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, Stevens RD, Bain JR, Newgard CB, Farese RV, Sr., Hevener AL, Farese RV Jr. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007;6:69-78.
51. Liang JS, Oelkers P, Guo C, Chu PC, Dixon JL, Ginsberg HN, Sturley SL. Overexpression of human diacylglycerol acyltransferase 1, acyl-coa: cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH777 cells. J Biol Chem. 2004;279:44938-44944.
52. Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes. 2004;53(suppl 1):S36-S42.
53. Qiu W, Federico L, Naples M, Avramoglu RK, Meshkani R, Zhang J, Tsai J, Hussain M, Dai K, Iqbal J, Kontos CD, Horle Y, Suzuki A, Adell K. Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. Hepatology. 2008;48: 1799-1809.
54. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Lizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113: 1774-1783.
55. Wetterau JR. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-150.
56. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073-1081.
57. Au WS, Kung HF, Lin MC. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38. Diabetes. 2003;52:1073-1080.
58. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes. 2005;54:1676-1683.
59. Kamagate A, Qu S, Perdomo G, Kim DH, Slusher S, Meseck M, Dong HH. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008;118:2347-2364.
60. Chuang SS, Zhuang HM, Reisher SR, Feinstein SI, Das HK. Transcriptional regulation of the apolipoprotein B-100 gene: identification of cis-acting elements in the first nontranslated exon of the human apolipoprotein B-100 gene. Biochem Biophys Res Commun. 1995;215:394-404.
61. Yao Z, McLeod RS. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim Biophys Acta. 1994;1212:152-166.
62. Sparks JD, Zolfaghari R, Sparks CE, Smith HC, Fisher EA. Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats. J Clin Invest. 1992;89:1418-1430.
63. Pan M, Liang JS, Fisher EA, Ginsberg HN. Inhibition of translocation of nascent apolipoprotein B across the endoplasmic reticulum membrane is associated with selective inhibition of the synthesis of apolipoprotein B. J Biol Chem. 2000;275:27399-27405.